HIVR4P 2023, the 5th HIV Research for Prevention Conference, Lima, Peru, and virtually, 22-26 October 2023

HIVR4P 2023，第五届艾滋病毒预防研究会议，秘鲁利马，虚拟会议，2023 年 10 月 22-26 日

• 批准号: 10617933
• 负责人: Christopher C. Beyrer
• 金额: $ 140万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10617933
• 关键词: AIDS prevention; Address; Adherence; Adolescent and Young Adult; Affect; African; Applied Research; Area; Attention; Basic Science; Brazil; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Calibration; Cities; Clinical Trials; Collaborations; Communities; Complex; Country; Dapivirine; Disparity; Drug user; Effectiveness; Emergency response; Epidemic; Epidemiology; Face; Financial Support; Formulation; Fostering; Goals; Government; HIV; HIV Infections; HIV vaccine; Hearing; Hybrids; Incidence; Indigenous; Individual; Infection; Injectable; Injecting drug user; Injections; International; Intervention; Knowledge; Latin American; Leadership; Learning; Light; Male Circumcision; Maps; Misinformation; Modality; Oral; Outcome; Overdose; Participant; Pathway interactions; Persons; Peru; Population; Populations at Risk; Prevention; Prevention Research; Prevention program; Prevention trial; Primary Prevention; Provider; Public Health; Reporting; Research; Research Personnel; Risk; Role; Rural; Science; Scientific Advances and Accomplishments; Scientist; System; Technology; Therapeutic; Time; Travel; Vaccine Research; Vaccines; Vaginal Ring; Woman; Work; Writing; community barrier; cost; design; disinformation; efficacy trial; girls; implementation science; innovation; low and middle-income countries; men; men who have sex with men; multidisciplinary; neutralizing antibody; new technology; next generation; novel; novel strategies; personalized approach; pre-exposure prophylaxis; prevent; programs; response; sex; small molecule; substance use; substance user; suburb; success; symposium; synergism; transgender; transmission process; uptake; vaccine hesitancy; virtual; willingness

Project Summary UNAIDS set ambitious prevention goals and targets for HIV incidence reductions for 2020. We were not on a trajectory for success for those goals before the COVID-19 pandemic, and are at risk of further expansion of HIV epidemics. Declines in surveillance capacity also threaten our ability to assess HIV epidemic trajectories in many settings of risk. We face daunting challenges of ongoing transmission, and of growing gaps and disparities in primary prevention. Yet the existing and expanding toolkit for biomedical prevention of HIV infection has never had as much diversity, and as many high efficacy options, as today. Adolescents and younger adults in African settings and in key populations globally continue to bear the greatest burdens of HIV incidence, and to have the greatest challenges using and benefitting from biomedical HIV prevention advances. This population will be at the center of HIVR4P 2023. A particular focus will also be made on people who inject drugs or who use substances in sexual settings and have been understudied and underserved in HIV prevention. In the field of HIV vaccines, the COVID-19 pandemic highlighted new threats in terms of vaccines hesitancy. It is time now to investigate and report on new ways to addressing hesitancy and to understanding barriers to the uptake of novel HIV vaccines, prevention technologies and approaches. HIVR4P 2023, the 5th HIV Research for Prevention Conference taking place from 22 to 26 October 2023 in Lima, Peru, will be an opportunity for the HIV prevention community to hear, debate and weigh new scientific evidence, and to assess the increasingly complex prevention landscape and the next generation of research questions, including those for HIV vaccines, and the interactions of vaccines with non-vaccine prevention modalities. Lima was chosen as the host city to highlight scientific excellence in prevention research in the Latin American region while also drawing attention to the spiraling vulnerabilities and epidemics in the region. To facilitate everyone’s access to the conference regardless of their ability or willingness to travel, and recognizing that potential obstacles - including access to COVID-19 vaccines - might prevent key stakeholders particularly from countries with a high burden of HIV from travelling internationally, HIVR4P 2023 will be a fully hybrid conference. It will connect the two audiences both in Lima, which will provide a compelling venue for HIVR4P 2023 as a leading center of HIV prevention science, and online via the virtual conference platform. Specific aims for HIVR4P 2023 are to: 1. Convene the world’s experts in HIV prevention and related fields to advance scientific knowledge, present new research findings, and enhance global scientific and community collaborations 2. Advance HIV prevention technologies and implementation approaches that are tailored to the needs of those most at risk including adolescents and young adults, men who have sex with men, people who use drugs, sex workers, and transgender people globally, and women and girls in high-burden settings 3. Refine HIV prevention research agendas to reflect identified opportunities and knowledge gaps, including: Next generation HIV vaccines and bNAbs; hesitancy and misinformation; smarter delivery systems for small molecules, including longer-acting PrEP, depo formulation and multi-purpose technologies 4. Assess the state of the art of HIV vaccine research in light of the remarkable success of the COVID-19 vaccine enterprise, including the role of non-vaccine interventions in the next generation of HIV vaccine efficacy trials. The scientific program will consist of five thematic areas: basic science; PrEP and ARV-based prevention; Vaccines and bNAbs clinical trials; other prevention modalities and cross-cutting issues; applied and implementation science. The scientific program is developed by a multi-disciplinary international Organizing Committee. Cross-cutting aspects will be highlighted in plenary talks that also connect the science with community and leadership perspectives. Additionally, bridging sessions are designed to cut across the different thematic areas to provide opportunities for multi-disciplinary, multi-perspective dialogues, often using interactive formats. The participation of young researchers, basic scientists and researchers in related fields will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following HIVR4P 2023.

项目摘要 联合国艾滋病规划署制定了雄心勃勃的预防目标和2020年降低艾滋病毒发病率的目标。我们不是在一个 在COVID-19大流行之前，这些目标的成功轨迹，并面临艾滋病毒进一步扩张的风险 流行病监测能力的下降也威胁到我们在许多国家评估艾滋病毒流行轨迹的能力。 风险设置。我们面临着不断传播的严峻挑战，面临着日益扩大的差距和差距， 初级预防。然而，现有的和不断扩大的艾滋病毒感染生物医学预防工具包从未 和今天一样有着多样性和高效的选择。非洲的青少年和年轻人 在全球范围内，艾滋病毒感染者和关键人群仍然承受着最大的负担， 利用和受益于生物医学艾滋病毒预防的进步是最大的挑战。这一人口将在 HIVR 4P 2023的中心。还将特别关注注射毒品者或吸毒者， 在性环境中使用药物，在艾滋病毒预防方面研究不足，服务不足。领域的 艾滋病毒疫苗，COVID-19大流行凸显了疫苗犹豫方面的新威胁。现在应当 调查和报告解决犹豫和了解吸收新知识的障碍的新方法 艾滋病毒疫苗、预防技术和方法。 HIVR 4P 2023，第五届艾滋病毒预防研究会议将于2023年10月22日至26日在 秘鲁利马将是艾滋病毒预防界听取、辩论和权衡新的科学成果的一个机会。 评估日益复杂的预防形势和下一代研究 问题，包括艾滋病毒疫苗问题，以及疫苗与非疫苗预防的相互作用 方式。利马被选为主办城市，以突出拉丁美洲预防研究的科学卓越性。 同时也提请注意该区域日益严重的脆弱性和流行病。 为每个人参加会议提供便利，无论他们是否有能力或是否愿意旅行， 认识到潜在的障碍--包括获得COVID-19疫苗--可能会阻止关键利益相关者 特别是来自国际旅行造成艾滋病毒高负担的国家，HIVR 4P 2023将是一个全面的 混合会议。它将连接利马的两个观众，这将为 HIVR 4P 2023作为艾滋病毒预防科学的领先中心，并通过虚拟会议平台在线。 HIVR 4P 2023的具体目标是： 1.召集全世界艾滋病毒预防和相关领域的专家，促进科学知识， 展示新的研究成果，加强全球科学和社区合作 2.推进艾滋病毒预防技术和实施方法，以适应 高危人群包括青少年和年轻人、男男性行为者、吸毒者、 毒品、性工作者和跨性别者，以及高负担环境中的妇女和女孩 3.完善艾滋病毒预防研究议程，以反映已查明的机会和知识差距，包括： 下一代艾滋病毒疫苗和bNAb;犹豫和错误信息;更智能的小型交付系统 分子，包括长效PrEP，depo配方和多用途技术 4.鉴于COVID-19取得的显著成功，评估艾滋病毒疫苗研究的最新水平 疫苗企业，包括非疫苗干预措施在下一代艾滋病毒疫苗中的作用 功效试验 科学方案将包括五个专题领域：基础科学; PrEP和基于ARV的预防; 疫苗和bNAb临床试验;其他预防方式和交叉问题;应用和 执行科学。该科学计划是由一个多学科的国际组织开发的， 以马克思跨领域的方面将在全体会议上强调，也将科学与 社区和领导的观点。此外，桥接会话旨在跨越不同的 主题领域，为多学科、多视角对话提供机会，通常使用互动 格式.青年研究人员、基础科学家和相关领域的研究人员的参与， 通过积极征求相关科学意见和提供具体的财政支持， 远程访问选项。会议的关键科学将在区域会议上传播和讨论。 根据HIVR 4P 2023。